We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

61 hedge funds and large institutions have $39.8M invested in ImmunityBio in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 17

21% more capital invested

Capital invested by funds: $32.8M → $39.8M (+$6.98M)

0.15% less ownership

Funds ownership: 13.74% → 13.59% (-0.15%)

5% less funds holding

Funds holding: 64 → 61 (-3)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
61
Holders Change
-3
Holders Change %
-4.69%
% of All Funds
1.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
23
Reduced
17
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$570K
2
BCM
Bridgeway Capital Management
Texas
+$237K
3
JP Morgan Chase
JP Morgan Chase
New York
+$201K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$80.8K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$62.6K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$367K
2
Millennium Management
Millennium Management
New York
-$237K
3
Goldman Sachs
Goldman Sachs
New York
-$162K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$152K
5
UBS Group
UBS Group
Switzerland
-$131K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
51
BNP Paribas Financial Markets
France
$3.75K – – –
Macquarie Group
52
Macquarie Group
Australia
$3K -$7.59K -2,400 -73%
Bank of Montreal
53
Bank of Montreal
Ontario, Canada
$2K -$6 -2 -0.5%
AG
54
Advisor Group
Arizona
$2K – – –
Daiwa Securities Group
55
Daiwa Securities Group
Japan
$2K – – –
PNC Financial Services Group
56
PNC Financial Services Group
Pennsylvania
$2K – – –
Group One Trading
57
Group One Trading
Illinois
$2K +$1.58K +500 New
Susquehanna International Group
58
Susquehanna International Group
Pennsylvania
– -$82K -26,837 Closed
CS
59
Credit Suisse
Switzerland
– -$41K -13,323 Closed
PP
60
Paloma Partners
Connecticut
– -$34K -10,958 Closed
BAM
61
Barrett Asset Management
New York
– -$23K -7,500 Closed
CG
62
Cutler Group
California
– -$10K -3,500 Closed
Manulife (Manufacturers Life Insurance)
63
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$8K -2,567 Closed
PIA
64
Piedmont Investment Advisors
North Carolina
– -$1K -483 Closed
SEI Investments
65
SEI Investments
Pennsylvania
– -$1K -329 Closed
Simplex Trading
66
Simplex Trading
Illinois
– -$680 -215 -77%
TRCT
67
Tower Research Capital (TRC)
New York
– +$237 +75 New
1 2
3

IBRX Hedge Fund Activity: Q3 2018 in Review

61 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q3 2018, worth a combined $39.8M — up 21% from $32.8M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of IBRX and 5 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 23 added.

The largest buyer was Renaissance Technologies, adding an estimated $570K. The largest seller was Morgan Stanley, cutting an estimated $367K.

  • 61 institutional investors held ImmunityBio (IBRX) as of Q3 2018, down from 64 in Q2 2018.
  • Funds reported $39.8M of ImmunityBio stock for Q3 2018, up 21% quarter-over-quarter.
  • 5 funds opened new ImmunityBio positions in Q3 2018 and 8 closed out, a net change of -3 holders.
  • The largest ImmunityBio buyer in Q3 2018 was Renaissance Technologies, an estimated $570K added.
  • The largest ImmunityBio seller in Q3 2018 was Morgan Stanley, an estimated $367K sold.

Based on aggregated 13F filings for Q3 2018.